Kwality Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.7K Cr
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Kwality Pharmaceuticals targets INR650-700 crores revenue in FY27 with EBITDA margins around 26-28%, aiming INR100 crores PAT.
From Kwality Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Price
₹3,358
Market Cap
₹2.7K Cr
P/E Ratio
39.1
How does Kwality Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Kwality Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Kwality Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹157 Cr, net profit ₹25 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores.
- →FY27: Expecting INR800-850 crores revenue with 28% EBITDA margin; oncology to rise to approx. INR150 crores.
- →FY29 Target: INR1,000 crores revenue with 30% EBITDA margin; oncology expected to contribute INR300 crores (~30%).
- →Registrations: 55 submissions made in Mexico (FY26), expecting all approved by end of 2027, with 25-30 more submissions planned in FY27.
- →Biosimilars & Hormones: Anticipated INR200 crores revenue by FY29, viewed as incremental beyond INR1,000 crores target.
- →Geography-wise Growth: Significant contributions from Germany (high-regulated market), Mexico, Colombia (LATAM), Algeria and MENA regions, GCC, Russia, and Southeast Asia.
- →Product Mix: Shift towards high regulated markets with better margins expected; 25-30% from oncology, 70% from other segments by FY29.
- →Working capital expected to improve; capex of INR90-100 crores planned each in FY27 and FY28 for expansions and R&D.
📈 Profitability & Margins
- →Kwality Pharmaceuticals targets INR650-700 crores revenue in FY27 with EBITDA margins around 26-28%, aiming INR100 crores PAT.
- →By FY28, revenue guidance is INR800-850 crores with EBITDA margins near 28%.
- →FY29 revenue target is INR1,000 crores with 30% EBITDA margins driven by oncology and regulated market growth.
- →Hormones and biologics expected to add approximately INR200 crores revenue by FY29, potentially exceeding INR1,000 crores total revenue.
- →Operating margins expected to improve from 24% (FY26) to 30% by FY29 due to higher regulated market mix and better pricing.
- →Despite rising input costs, margin expansion projected as regulated market products deliver better profitability.
- →Working capital cycle expected to improve, supporting stable interest costs and cash flows.
- →EPS growth aligns with rising profitability and margin expansion as business scale increases, backed by improved operational efficiencies.
🏗️ Capital Expenditure Plans
- →Total capex planned for hormones, oncology expansion, biosimilars with clinical trials, R&D, and bioequivalence is around INR 260–270 crores.
- →INR 46 crores of capex already done in FY26.
- →Planned capex for FY27 is approximately INR 90 crores.
- →Planned capex for FY28 is around INR 90–100 crores.
- →Capex so far financed through existing working capital and re-utilization of bank loans without increasing borrowings.
- →Key ongoing projects: hormone manufacturing building (30–40% machinery cost already paid), oncology expansion with new automated line and three lyophilizers, biosimilar manufacturing expansion including a finishing plant in Algeria.
- →Capex execution to fully ramp up from July onwards, with cash flows expected to fund remaining capex.
💰 Fundraising & Capital Structure
- →No new increase in loans or limits has been reported; existing working capital and bank loans are being efficiently managed by re-utilizing repayments.
- →Capex of INR46-50 crores till now has been funded through existing working capital and loan repayments without raising new debt.
- →Working capital cycle is expected to improve between July to October, enabling capex funding from revenues.
- →Future capex for hormones, oncology expansion, biosimilars, clinical trials, and R&D is estimated at INR90 crores each in FY27 and FY28, likely to be funded internally.
- →Annual interest costs are expected to remain stable, indicating no planned increase in borrowings.
- →No explicit mention of equity fundraising or fresh debt issuance in the disclosed period.
📋 Order Book & Pipeline
- →INR60-70 crores were stuck in payments for the last 1.5 to 2 quarters due to disruptions like the Strait of Hormuz situation.
- →Out of the pending INR60 crores, around 40% (approx. INR25 crores) has already been realized.
- →Complete realization of the pending amount is expected by June or July 2026.
- →Debtor days have recently improved and come down to around 170 days and are expected to stabilize between 150-160 days.
- →Inventory days are maintained roughly at 80-90 days.
- →The company is gradually recovering from disruptions, leading to better cash realization from its order book.
Key Metrics
Frequently Asked Questions
What were Kwality Pharmaceuticals Ltd Q4 FY26 results?
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Kwality Pharmaceuticals targets INR650-700 crores revenue in FY27 with EBITDA margins around 26-28%, aiming INR100 crores PAT.
What is Kwality Pharmaceuticals Ltd share price analysis?
Kwality Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.1 with a market cap of ₹2,655 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kwality Pharmaceuticals Ltd planning capital expenditure?
Total capex planned for hormones, oncology expansion, biosimilars with clinical trials, R&D, and bioequivalence is around INR 260–270 crores.
Keep Kwality Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.